Search Results - "Burrows, Francis"

This result is not displayed to guests.
Login for full access.

Drugging the Cancer Chaperone HSP90.

Authors: WORKMAN, PAUL BURROWS, FRANCIS NECKERS, LEN et al.

Source: Annals of the New York Academy of Sciences. Dec2007, Vol. 1113, p202-216. 15p.

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Authors: Kamal, Adeela Thao, Lia Sensintaffar, John et al.

Source: Nature. 9/25/2003, Vol. 425 Issue 6956, p407. 4p.

Subjects: Heat shock proteins, Cancer cells, Binding sites

Purified herpes simplex virus thymidine kinase retroviral particles:.

Authors: Burrows, Francis J Gore, Martin Smiley, W Russell et al.

Source: Cancer Gene Therapy. Jan2002, Vol. 9 Issue 1, p87. 9p.

DEVELOPING AN ONLINE COMMUNITY.

Authors: Burrows, Francis

Source: Charities Management. 2011, Issue 78, p44-46. 3p.

Hsp90 Activation and Cell Cycle Regulation.

Authors: Burrows, Francis Hong Zhang Kama, Adeela

Source: Cell Cycle. Dec2004, Vol. 3 Issue 12, p1530-1536. 7p.

Inquest; Parting words.

Authors: BURROWS, Francis

Source: London Mercury; December 1928, Vol. 19, p130-131, 2p

This result is not displayed to guests.
Login for full access.

Life's journey.

Authors: BURROWS, Francis

Source: London Mercury; July 1928, Vol. 18, p242-242, 1p

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.

Authors: Alonso-Alonso, Ruth Mondéjar, Rufino Martínez, Nerea et al.

Source: Scientific Reports. 4/21/2020, Vol. 10 Issue 1, p1-11. 11p.

The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.

Authors: Pallis, Monica Abdul-Aziz, Amina Burrows, Francis et al.

Source: British Journal of Haematology. Oct2012, Vol. 159 Issue 2, p191-203. 13p. 6 Graphs.

Therapeutic and diagnostic implications of Hsp90 activation

Authors: Kamal, Adeela Boehm, Marcus F. Burrows, Francis J.

Source: Trends in Molecular Medicine. Jun2004, Vol. 10 Issue 6, p283-290. 8p.

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.

Authors: Dakappagari, Naveen Neely, Laura Tangri, Shabnam et al.

Source: Biomarkers. Feb2010, Vol. 15 Issue 1, p31-38. 8p. 4 Graphs.

Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients.

Authors: Fujii, Shigeyuki Huang, Sharon Fong, Tim C et al.

Source: Cancer Gene Therapy. Sep2000, Vol. 7 Issue 9, p1220. 11p.

Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms.

Authors: Kruse, Carol A Lamb, Carilee Hogan, Suzanne et al.

Source: Cancer Gene Therapy. Jan2000, Vol. 7 Issue 1, p118. 10p.

Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.

Authors: Manikandan, Dinesh Babu Jagadeeshan, Sankar Mathukkada, Sooraj et al.

Source: Neoplasia. May2025, Vol. 63, pN.PAG-N.PAG. 1p.

CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target.

Authors: Malik, Shivani Westcott, Jill M. Brekken, Rolf A. et al.

Source: Cancers. Jan2022, Vol. 14 Issue 1, p86. 1p.

Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas.

Authors: Kessler, Linda Malik, Shivani Leoni, Mollie et al.

Source: Cancers. Nov2021, Vol. 13 Issue 21, p5310. 1p.

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Authors: Levin, Nancy Spencer, Andrew Harrison, Simon J. et al.

Source: British Journal of Haematology. Sep2016, Vol. 174 Issue 5, p711-720. 10p.

Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.

Authors: Jagadeeshan, Sankar Suryamohan, Kushal Shin, Nara et al.

Source: Oral Oncology. Feb2024, Vol. 149, pN.PAG-N.PAG. 1p.